Vollenweider, FX, Kometer, M. The neurobiology of psychedelic drugs: implications
for the treatment of mood disorders. Nat Rev
2010; 11: 642–51.
Berman, RM, Cappiello, A, Anand, A, Oren, DA, Heninger, GR, Charney, DS, et al. Antidepressant effects of ketamine in
depressed patients. Biol Psychiatry
2000; 47: 351–4.
Hashimoto, K. Emerging role of glutamate in the pathophysiology of
major depressive disorder. Brain Res Rev
2009; 61: 105–23.
Murrough, JW. Ketamine as a novel antidepressant: from synapse to
behavior. Clin Pharmacol Ther
2012; 91: 303–9.
Moghaddam, B, Adams, B, Verma, A, Daly, D. Activation of glutamatergic neurotransmission by
ketamine: a novel step in the pathway from NMDA receptor blockade to
dopaminergic and cognitive disruptions associated with the prefrontal
cortex. J Neurosci
1997; 17: 2921–7.
Zarate, C Jr, Machado-Vieira, R, Henter, I, Ibrahim, L, Diazgranados, N, Salvadore, G. Glutamatergic modulators: the future of treating
Harv Rev Psychiatry
Li, N, Lee, B, Liu, RJ, Banasr, M, Dwyer, JM, Iwata, M, et al. mTOR-dependent synapse formation underlies
the rapid antidepressant effects of NMDA antagonists.
2010; 329: 959–64.
Li, N, Liu, RJ, Dwyer, JM, Banasr, M, Lee, B, Son, H, et al. Glutamate
N-methyl-d-aspartate receptor antagonists rapidly
reverse behavioral and synaptic deficits caused by chronic stress
exposure. Biol Psychiatry
2011; 69: 754–61.
aan het Rot, M, Zarate, CA Jr, Charney, DS, Mathew, SJ. Ketamine for depression: where do we go from
2012; 72: 537–47.
Diazgranados, N, Ibrahim, L, Brutsche, NE, Newberg, A, Kronstein, P, Khalife, S, et al. A randomized add-on trial of an
N-methyl-d-aspartate antagonist in
treatment-resistant bipolar depression. Arch Gen
Zarate, CA Jr, Brutsche, NE, Ibrahim, L, Franco-Chaves, J, Diazgranados, N, Cravchik, A, et al. Replication of ketamine's antidepressant
efficacy in bipolar depression: a randomized controlled add-on
trial. Biol Psychiatry
2012: 71: 939–46.
Zarate, CA Jr, Singh, JB, Carlson, PJ, Brutsche, NE, Ameli, R, Luckenbaugh, DA, et al. A randomized trial of an
N-methyl-d-aspartate antagonist in treatment-resistant
major depression. Arch Gen Psychiatry
2006; 63: 856–64.
Sos, P, Klirova, M, Novak, T, Kohutova, B, Horacek, J, Palenicek, T. Relationship of ketamine's antidepressant and
psychotomimetic effects in unipolar depression.
Neuro Endocrinol Lett
2013; 34: 287–93.
Price, RB, Iosifescu, DV, Murrough, JW, Chang, LC, Al Jurdi, RK, Iqbal, SZ, et al. Effects of ketamine on explicit and implicit
suicidal cognition: a randomized controlled trial in treatment-resistant
depression. Depress Anxiety
2014; 31: 335–43.
Murrough, JW, Iosifescu, DV, Chang, LC, Al Jurdi, RK, Green, CE, Perez, AM, et al. Antidepressant efficacy of ketamine in
treatment-resistant major depression: a two-site randomized controlled
trial. Am J Psychiatry
2013; 170: 1134–42.
aan het Rot, M, Collins, KA, Murrough, JW, Perez, AM, Reich, DL, Charney, DS, et al. Safety and efficacy of repeated-dose
intravenous ketamine for treatment-resistant depression.
2010; 67: 139–45.
Ibrahim, L, Diazgranados, N, Franco-Chaves, J, Brutsche, N, Henter, ID, Kronstein, P, et al. Course of improvement in depressive symptoms
to a single intravenous infusion of ketamine vs add-on riluzole: results
from a 4-week, double-blind, placebo-controlled study.
2012; 37: 1526–33.
Mathew, SJ, Murrough, JW, aan het Rot, M, Collins, KA, Reich, DL, Charney, DS. Riluzole for relapse prevention following
intravenous ketamine in treatment-resistant depression: a pilot
randomized, placebo-controlled continuation trial.
Int J Neuropsychopharmacol
Blonk, MI, Koder, BG, van den Bemt, PM, Huygen, FJ. Use of oral ketamine in chronic pain management: a
review. Eur J Pain
2010; 14: 466–72.
Fisher, K, Coderre, TJ, Hagen, NA. Targeting the N-methyl-d-aspartate
receptor for chronic pain management. Preclinical animal studies, recent
clinical experience and future research directions.
J Pain Symptom Manage
2000; 20: 358–73.
Clements, JA, Nimmo, WS, Grant, IS. Bioavailability, pharmacokinetics, and analgesic
activity of ketamine in humans. J Pharm
1982; 71: 539–42.
Chong, CC, Schug, SA, Page-Sharp, M, Ilett, KF. Bioavailability of ketamine after oral or sublingual
administration. Pain Medicine
2006; 7: 469.
Yanagihara, Y, Ohtani, M, Kariya, S, Uchino, K, Hiraishi, T, Ashizawa, N, et al. Plasma concentration profiles of ketamine and
norketamine after administration of various ketamine preparations to
healthy Japanese volunteers. Biopharm Drug
Paslakis, G, Gilles, M, Meyer-Lindenberg, A, Deuschle, M. Oral administration of the NMDA receptor antagonist
S-ketamine as add-on therapy of depression: a case
2010; 43: 33–5.
McNulty, JP, Hahn, K. Compounded oral ketamine.
Int J Pharm Compd
2012; 16: 364–8.
Irwin, SA, Iglewicz, A. Oral ketamine for the rapid treatment of depression
and anxiety in patients receiving hospice care. J
2010; 13: 903–8.
Irwin, SA, Iglewicz, A, Nelesen, RA, Lo, JY, Carr, CH, Romero, SD, et al. Daily oral ketamine for the treatment of
depression and anxiety in patients receiving hospice care: a 28-day
open-label proof-of-concept trial. J Palliat
2013; 16: 958–65.
De Gioannis, A, De Leo, D. Oral ketamine augmentation for chronic suicidality
in treatment-resistant depression. Aust NZ J
2014; 48: 686.
Lara, DR, Bisol, LW, Munari, LR. Antidepressant, mood stabilizing and procognitive
effects of very low dose sublingual ketamine in refractory unipolar and
bipolar depression. Int J
2013; 16: 2111–7.
Kaviani, N, Khademi, A, Ebtehaj, I, Mohammadi, Z. The effect of orally administered ketamine on
requirement for anesthetics and postoperative pain in mandibular molar
teeth with irreversible pulpitis. J Oral
2011; 53: 461–5.
Villanueva-Perez, VL, Cerdá-Olmedo, G, Samper, JM, Mínguez, A, Monsalve, V, Bayona, MJ, et al. Oral ketamine for the treatment of type I
complex regional pain syndrome. Pain
Klepstad, P, Borchgrevink, P, Hval, B, Flaat, S, Kaasa, S. Long-term treatment with ketamine in a 12-year-old
girl with severe neuropathic pain caused by a cervical spinal
tumor. J Pediatr Hematol Oncol
2001; 23: 616–9.
Kapural, L, Kapural, M, Bensitel, T, Sessler, DI. Opioid-sparing effect of intravenous outpatient
ketamine infusions appears short-lived in chronic-pain patients with high
opioid requirements. Pain Physician
2010; 13: 389–94.
Joseph, C, Gaillat, F, Duponq, R, Lieven, R, Baumstarck, K, Thomas, P, et al. Is there any benefit to adding intravenous
ketamine to patient-controlled epidural analgesia after thoracic surgery?
A randomized double-blind study. Eur J
Hu, J, Liao, Q, Zhang, F, Tong, J, Ouyang, W. Chronic postthoracotomy pain and perioperative
ketamine infusion. J Pain Palliat Care
2014; 28: 117–21.
Tena, B, Gomar, C, Rios, J. Perioperative epidural or intravenous ketamine does
not improve the effectiveness of thoracic epidural analgesia for acute
and chronic pain after thoracotomy. Clin J
Yazigi, A, Abou-Zeid, H, Srouji, T, Madi-Jebara, S, Haddad, F, Jabbour, K. The effect of low-dose intravenous ketamine on
continuous intercostal analgesia following thoracotomy.
Ann Card Anaesth
2012; 15: 32–8.
Barreveld, AM, Correll, DJ, Liu, X, Max, B, McGowan, JA, Shovel, L, et al. Ketamine decreases postoperative pain scores
in patients taking opioids for chronic pain: results of a prospective,
randomized, double-blind study. Pain Med
2013; 14: 925–34.
Vick, PG, Lamer, TJ. Treatment of central post-stroke pain with oral
2001; 92: 311–3.
Pouget, P, Wattiez, N, Rivaud-Péchoux, S, Gaymard, B. Rapid development of tolerance to sub-anaesthetic
dose of ketamine: an oculomotor study in macaque monkeys.
2010; 209: 313–8.
Rocha, BA, Ward, AS, Egilmez, Y, Lytle, DA, Emmett-Oglesby, MW. Tolerance to the discriminative stimulus and
reinforcing effects of ketamine. Behav
1996; 7: 160–8.
Stevens, RW, Hain, WR. Tolerance to rectal ketamine in paediatric
1981; 36: 1089–93.
Byer, DE, Gould, AB Jr. Development of tolerance to ketamine in an infant
undergoing repeated anesthesia.
1981; 54: 255–6.
Livingston, A, Waterman, AE. The development of tolerance to ketamine in rats and
the significance of hepatic metabolism. Br J
1978; 64: 63–9.
Cumming, JF. The development of an acute tolerance to
ketamine. Anesth Analg
1976; 55: 788–91.
Chong, C, Schug, SA, Page-Sharp, M, Jenkins, B, Ilett, KF. Development of a sublingual/oral formulation of
ketamine for use in neuropathic pain: preliminary findings from a
three-way randomized, crossover study. Clin Drug
2009; 29: 317–24.
Brunette, KE, Anderson, BJ, Thomas, J, Wiesner, L, Herd, DW, Schulein, S. Exploring the pharmacokinetics of oral ketamine in
children undergoing burns procedures. Paediatr
2011; 21: 653–62.
Zimm, S, Collins, JM, Riccardi, R, O'Neill, D, Narang, PK, Chabner, B, et al. Variable bioavailability of oral
mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic
leukemia being optimally delivered?
N Engl J Med
1983; 308: 1005–9.
Harvey, VJ, Slevin, ML, Joel, SP, Smythe, MM, Johnston, A, Wrigley, PF. Variable bioavailability following repeated oral
doses of etoposide. Eur J Cancer Clin
1985; 21: 1315–9.
Di, WL, Kadva, A, Johnston, A, Silman, R. Variable bioavailability of oral
melatonin. N Engl J Med
1997; 336: 1028–9.
Lund, J, Thayssen, P, Mengel, H, Pedersen, OL, Kristensen, CB, Gram, LF. Paroxetine: pharmacokinetics and cardiovascular
effects after oral and intravenous single doses in man.
Acta Pharmacol Toxicol (Copenh)
1982; 51: 351–7.
Weber, F, Wulf, H, Gruber, M, Biallas, R. S-ketamine and s-norketamine plasma concentrations
after nasal and i.v. administration in anesthetized
children. Paediatr Anaesth
2004; 14: 983–8.
Rolan, P, Lim, S, Sunderland, V, Liu, Y, Molnar, V. The absolute bioavailability of racemic ketamine
from a novel sublingual formulation. Br J Clin
2014; 77: 1011–6.
Morgan, CJ, Muetzelfeldt, L, Curran, HV. Consequences of chronic ketamine self-administration
upon neurocognitive function and psychological wellbeing: a 1-year
longitudinal study. Addiction
2010; 105: 121–33.
Bowdle, TA, Radant, AD, Cowley, DS, Kharasch, ED, Strassman, RJ, Roy-Byrne, PP. Psychedelic effects of ketamine in healthy
volunteers: relationship to steady-state plasma
1998; 88: 82–8.
Liebrenz, M, Borgeat, A, Leisinger, R, Stohler, R. Intravenous ketamine therapy in a patient with a
treatment-resistant major depression. Swiss Med
2007; 137: 234–6.
Malinovsky, JM, Cozian, A, Lepage, JY, Mussini, JM, Pinaud, M, Souron, R. Ketamine and midazolam neurotoxicity in the
1991; 75: 91–7.
Malinovsky, JM, Lepage, JY, Cozian, A, Mussini, JM, Pinaudt, M, Souron, R. Is ketamine or its preservative responsible for
neurotoxicity in the rabbit?
1993; 78: 109–15.
Gomes, LM, Garcia, JB, Ribamar, JS Jr, Nascimento, AG. Neurotoxicity of subarachnoid preservative-free
S(+)-ketamine in dogs. Pain Physician
Sun, L, Li, Q, Li, Q, Zhang, Y, Liu, D, Jiang, H, et al. Chronic ketamine exposure induces permanent
impairment of brain functions in adolescent cynomolgus
monkeys. Addict Biol
2014; 19: 185–94.
Edward Roberts, R, Curran, HV, Friston, KJ, Morgan, CJ. Abnormalities in white matter microstructure
associated with chronic ketamine use.
2014; 39: 329–38.
Freeman, TP, Morgan, CJ, Pepper, F, Howes, OD, Stone, JM, Curran, HV. Associative blocking to reward-predicting cues is
attenuated in ketamine users but can be modulated by images associated
with drug use. Psychopharmacology (Berl)
Morgan, CJ, Curran, HV, Independent Scientific Committee on Drugs. Ketamine
use: a review. Addiction
Shahani, R, Streutker, C, Dickson, B, Stewart, RJ. Ketamine-associated ulcerative cystitis: a new
clinical entity. Urology
2007; 69: 810–2.
Tsai, TH, Cha, TL, Lin, CM, Tsao, CW, Tang, SH, Chuang, FP, et al. Ketamine-associated bladder
dysfunction. Int J Urol
2009; 16: 826–9.
Correll, GE, Futter, GE. Two case studies of patients with major depressive
disorder given low-dose (subanesthetic) ketamine
infusions. Pain Med
2006; 7: 92–5.
Kannan, TR, Saxena, A, Bhatnagar, S, Barry, A. Oral ketamine as an adjuvant to oral morphine for
neuropathic pain in cancer patients. J Pain
2002; 23: 60–5.
Haines, DR, Gaines, SP. N of 1 randomised controlled trials of oral ketamine
in patients with chronic pain. Pain
1999; 83: 283–7.
Bredlau, AL, McDermott, MP, Adams, HR, Dworkin, RH, Venuto, C, Fisher, SG, et al. Oral ketamine for children with chronic pain:
a pilot phase I study. J Pediatr
Mercadante, S, Arcuri, E, Tirelli, W, Casuccio, A. Analgesic effect of intravenous ketamine in cancer
patients on morphine therapy: a randomized, controlled, double-blind,
crossover, double-dose study. J Pain Symptom
2000; 20: 246–52.
Schwartzman, RJ, Alexander, GM, Grothusen, JR, Paylor, T, Reichenberger, E, Perreault, M. Outpatient intravenous ketamine for the treatment of
complex regional pain syndrome: a double-blind placebo controlled
2009; 147: 107–15.
Beardsley, PM, Balster, RL. Behavioral dependence upon phencyclidine and
ketamine in the rat. J Pharmacol Exp
1987; 242: 203–11.
Klein, M, Calderon, S, Hayes, B. Abuse liability assessment of
neuroprotectants. Ann NY Acad Sci
1999; 890: 515–25.
Corazza, O, Assi, S, Schifano, F. From “Special K” to “Special M”: the evolution of
the recreational use of ketamine and methoxetamine.
CNS Neuroscience Ther
2013; 19: 454–60.
Muetzelfeldt, L, Kamboj, SK, Rees, H, Taylor, J, Morgan, CJ, Curran, HV. Journey through the K-hole: phenomenological aspects
of ketamine use. Drug Alcohol Depend
2008; 95: 219–29.
Argoff, CE, Stanos, SP, Wieman, MS. Validity testing of patient objections to acceptance
of tamper-resistant opioid formulations. J Pain
2013; 6: 367–73.
Schatzberg, AF. A word to the wise about ketamine.
Am J Psychiatry
2014; 171: 262–4.
Caddy, C, Amit, BH, McCloud, TL, Rendell, JM, Furukawa, TA, McShane, R, et al. Ketamine and other glutamate receptor
modulators for depression in adults. Cochrane
Database Syst Rev
Levine, J, Schooler, NR. SAFTEE: a technique for the systematic assessment of
side effects in clinical trials. Psychopharmacol
1986; 22: 343–81.